CASP1 and viral infectious disease: Similarly, the presence of oligo-caspase specific inhibitors, targeted at caspases 1 and 4 (Belnacasan), 3 and 7 or 3, 6, 7, and 10, as well as their combination, resulted in at best marginal inhibitions to both the down-regulation of CD62L and the viral infections (Fig 3A and 3B, S4A and S4B Fig).